- Home
- EHLD vs CING Comparison
EHLD vs CING Comparison
Compare EHLD & CING Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EHLD
- CING
- Stock Information
- Founded
- EHLD 2024
- CING 2012
- Country
- EHLD Greece
- CING United States
- Employees
- EHLD N/A
- CING N/A
- Industry
- EHLD
- CING Biotechnology: Pharmaceutical Preparations
- Sector
- EHLD
- CING Health Care
- Exchange
- EHLD NYSE
- CING Nasdaq
- Market Cap
- EHLD 17.2M
- CING 16.2M
- IPO Year
- EHLD N/A
- CING 2021
- Fundamental
- Price
- EHLD $7.70
- CING $4.25
- Analyst Decision
- EHLD
- CING Strong Buy
- Analyst Count
- EHLD 0
- CING 4
- Target Price
- EHLD N/A
- CING $30.67
- AVG Volume (30 Days)
- EHLD 52.6K
- CING 106.4K
- Earning Date
- EHLD 08-15-2025
- CING 08-12-2025
- Dividend Yield
- EHLD 7.27%
- CING N/A
- EPS Growth
- EHLD N/A
- CING N/A
- EPS
- EHLD 4.74
- CING N/A
- Revenue
- EHLD $14,687,504.00
- CING N/A
- Revenue This Year
- EHLD N/A
- CING N/A
- Revenue Next Year
- EHLD N/A
- CING N/A
- P/E Ratio
- EHLD $1.63
- CING N/A
- Revenue Growth
- EHLD N/A
- CING N/A
- 52 Week Low
- EHLD $3.83
- CING $1.80
- 52 Week High
- EHLD $12.80
- CING $20.83
- Technical
- Relative Strength Index (RSI)
- EHLD N/A
- CING 53.17
- Support Level
- EHLD N/A
- CING $3.97
- Resistance Level
- EHLD N/A
- CING $4.26
- Average True Range (ATR)
- EHLD 0.00
- CING 0.27
- MACD
- EHLD 0.00
- CING -0.01
- Stochastic Oscillator
- EHLD 0.00
- CING 48.10
About EHLD EUROHOLDINGS LTD
Euroholdings Ltd is a provider of shipping transportation services. The company specializes in the ownership of vessels. The fleet of the company consists of containerships that transport container boxes providing scheduled service between ports.
About CING Cingulate Inc.
Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic area to use PTR technology to develop future product candidates.